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n platelets, the nitric oxide (NO)–induced cGMP response
is indicative of a highly regulated interplay of cGMP for-
mation and cGMP degradation. Recently, we showed
that within the NO-induced cGMP response in human
platelets, activation and phosphorylation of phosphodi-
esterase type 5 (PDE5) occurred. Here, we identify cyclic
GMP-dependent protein kinase I as the kinase responsible
for the NO-induced PDE5 phosphorylation. However, we
demonstrate that cGMP can directly activate PDE5 without
phosphorylation in platelet cytosol, most likely via binding
to the regulatory GAF domains. The reversal of activation was
slow, and was not completed after 60 min. Phosphorylation
I
 
enhanced the cGMP-induced activation, allowing it to occur
at lower cGMP concentrations. Also, in intact platelets, a
sustained NO-induced activation of PDE5 for as long as 60
min was detected. Finally, the long-term desensitization of
the cGMP response induced by a low NO concentration
reveals the physiological relevance of the PDE5 activation
within NO/cGMP signaling. In sum, we suggest NO-induced
activation and phosphorylation of PDE5 as the mechanism
for a long-lasting negative feedback loop shaping the
cGMP response in human platelets in order to adapt to the
amount of NO available.
 
Introduction
 
The signaling molecule nitric oxide (NO)* plays an important
role in the cardiovascular and nervous system under physio-
logical and pathophysiological conditions. An important
function of NO is the activation of NO-sensitive guanylyl
cyclase through its binding to the prosthetic heme group of
the enzyme. The resulting activation of guanylyl cyclase leads to
an enhanced conversion of GTP to the second messenger
cGMP (Koesling and Friebe, 1999). An elevated intracellular
cGMP concentration mediates a variety of cellular and physio-
logical responses, depending on the cell type and tissue. In
the vascular system, the relaxation of blood vessels and the
inhibition of platelet aggregation are mediated by cGMP
(Schwarz et al., 2001). Cyclic GMP exerts its effects through
activation of different effectors, such as cGMP-gated ion
channels (Biel et al., 1999), cGMP-dependent protein kinases
(Lohmann et al., 1997; Hofmann et al., 2000) and cGMP-
regulated phosphodiesterases (PDEs; Juilfs et al., 1999;
Francis et al., 2000).
In addition to cGMP formation, degradation of cGMP by
cyclic nucleotide PDEs determines intracellular cGMP levels.
Several different isoforms of PDEs are known to hydrolyze
cGMP, and are therefore potentially involved in controlling
the intracellular cGMP turnover. In platelets and smooth
muscle cells, an important regulator of cGMP levels is the
cGMP-binding cGMP-specific PDE (PDE5). The enzyme
is a homodimer with two regulatory, putative cGMP-binding
GAF domains (found in cGMP-phosphodiesterases, adenylyl
cyclases, and 
 
Escherichia coli
 
 FhlA) and one catalytic site per
monomer (Corbin and Francis, 1999); each monomer contains
a phosphorylation site that is conserved across species, e.g.,
in human, rat, bovine, canine, and murine isoforms.
PDE5 has been shown to be phosphorylated in vitro by
cyclic GMP-dependent protein kinase I (cGKI) and cyclic
AMP-dependent protein kinase (cAK; Corbin et al., 2000).
Phosphorylation of PDE5 requires binding of cGMP to the
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regulatory domains (Turko et al., 1998), and has been sug-
gested to enhance cGMP hydrolysis in vitro and in intact
cells (Wyatt et al., 1998; Rybalkin et al., 2001). An increase
in PDE5 activity induced by cGKI-mediated phosphoryla-
tion potentially represents an important feedback mecha-
nism to limit amplitude and duration of a cGMP signal in
cells that express this PDE isoform.
However, the functional relevance of PDE5 activation
and phosphorylation within the NO/cGMP signaling
pathway has not yet been thoroughly investigated. In plate-
lets, we have shown that NO leads to a rapid, biphasic
cGMP response that is indicative of a tight regulation of
cGMP-forming and -degrading activities (Mullershausen
et al., 2001). Furthermore, preincubation of platelets
with NO rapidly led to a reduction of the NO-induced
cGMP response, revealing short-term desensitization oc-
curring within the NO/cGMP signaling pathway. Al-
though cGMP formation by guanylyl cyclase remained un-
altered during the entire course of the cGMP response, the
activity of PDE5 was found to be enhanced in NO-incu-
bated platelets (Mullershausen et al., 2001). Therefore, the
rapid NO-induced desensitization of the system has been
attributed to an enhanced cGMP degradation through ac-
tivation of PDE5. With antibodies specific for the phos-
phorylated form of PDE5, the activation was shown to be
paralleled by phosphorylation. The components of the sig-
naling pathway that act downstream of NO and cause the
activation and phosphorylation of PDE5 in human plate-
lets are so far unknown. Moreover, the reversal of PDE5
activation and phosphorylation has not been investigated
in intact cells.
In the present paper, we identify the components of the
NO/cGMP signaling pathway that mediate PDE5 activa-
tion and phosphorylation in response to NO in intact
platelets. We demonstrate that cGMP by itself is able to
activate PDE5, most likely by binding to the GAF do-
mains of the enzyme, and we supply evidence that phos-
phorylation enhances the activation induced by cGMP. By
monitoring the decline in activity in platelet supernatant
and in intact platelets, we show that the NO-induced
PDE5 activation persists for over 1 h. In addition, we dem-
onstrate that the relatively small increase in PDE activity
induced by a physiologically occurring NO concentration
is sufficient to reduce the NO-induced cGMP response for
as long as 1 h.
 
Results
 
NO-induced activation and phosphorylation of PDE5 
in platelets depends on guanylyl cyclase stimulation
 
In platelets, NO is known to cause inhibition of aggrega-
tion by increasing the intracellular cGMP content and the
subsequent activation of cGMP-dependent protein kinase.
In these cells, PDE5 has been shown to be the relevant
PDE for cGMP degradation; recently, we showed that
the cGMP response induced by the NO-releasing agent
GSNO was paralleled by the activation and phosphoryla-
tion of PDE5 in the supernatant prepared from intact NO-
incubated platelets (Mullershausen et al., 2001). Here,
we used the guanylyl cyclase inhibitor 1H-[1,2,4]oxadia-
zolo[4,3-a]quinoxalin-1-one (ODQ), to find out whether
the NO effects on PDE5 depended on guanylyl cyclase–
catalyzed cGMP formation, and measured cytosolic PDE
activity after incubation of intact platelets with 1 
 
 
 
M of
the NO donor DEA-NO in the absence and presence of
ODQ. As can be seen in Fig. 1, NO caused an increase in
PDE5 activity (2.4-fold over basal) paralleled by phosphor-
ylation. Both NO-induced activation and phosphorylation
were abolished in the presence of ODQ, clearly demon-
strating that the effects of NO on PDE5 in platelets are
mediated by stimulation of guanylyl cyclase and the con-
comitant cGMP increase.
To obtain information on the activity state of cGKI,
we monitored the NO-induced phosphorylation of the
well-known substrate called vasodilator-activated stimulated
phosphoprotein (VASP) using a phosphospecific VASP anti-
body (Fig. 1 B, bottom). The antibody recognizes phosphor-
ylation of VASP at Ser-239; the shift in the apparent molec-
ular mass is caused by further phosphorylation of VASP at
Ser-157. As expected, in the presence of ODQ, phosphor-
ylation of VASP induced by NO was abolished.
Figure 1. NO-induced activation and phosphorylation of PDE5 is 
inhibited by ODQ. (A) Human platelets were incubated for 2 min 
without or with 1  M DEA-NO in the absence and presence of the 
guanylyl cyclase inhibitor ODQ (20  M), then platelets were lysed 
and PDE activity was determined in the cytosolic fractions. Data 
represent means   SD of three independent determinations in 
duplicate. (B) The DEA-NO–induced phosphorylation of PDE5 was 
detected in a Western blot; PDE5 content of the samples is also shown 
(top). The band seen below phospho-PDE5 is due to nonspecific 
binding of the antibody in human platelet samples. Bottom shows 
Western blot detection of phosphorylated VASP.T
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Removal of cGKI reduces cGMP-induced 
phosphorylation and activation of PDE5 
in platelet supernatant
 
As guanylyl cyclase–catalyzed cGMP formation was required
for the NO-induced activation and phosphorylation of
PDE5, we tested whether these effects could be induced by
cGMP in broken platelet preparations. In these experiments,
platelet supernatants were preincubated with 100 
 
 
 
M
cGMP. Subsequently, in this and all following cGMP prein-
cubation experiments, platelet supernatants were diluted to a
final cGMP concentration below at least 0.1 
 
 
 
M, and
PDE5 activity was then determined with 1 
 
 
 
M cGMP as
substrate. As shown in Fig. 2 B (bar 1) and Fig. 2 C (lane 1),
 
incubation of lysed platelets with cGMP led to activation
(1.9-fold) and phosphorylation of PDE5.
Next, we investigated the role of cGKI in the process of
phosphorylation and activation of PDE5 in platelet superna-
tants. To quantitatively remove cGKI, we precipitated the
enzyme from the platelet supernatant using Rp-8-AET-
cGMPS coupled to agarose beads. With immunoblot analysis
(Fig. 2 A, top), we confirmed that the majority of cGKI had
been cleared from the sample (lane 1 vs. lane 2); lane 3 shows
the signal after reconstitution with 0.2 
 
 
 
g exogenous cGKI.
Treatment with Rp-8-AET-cGMPS-agarose did not lead to a
loss of PDE5 activity in the supernatant (unpublished data),
demonstrating that PDE5 was not precipitated. Moreover,
equal amounts of PDE5 were present in the samples as con-
trolled by immunoblot analysis (Fig. 2 A, bottom).
The cGKI-containing, -depleted, and -reconstituted su-
pernatants were preincubated with 100 
 
 
 
M cGMP for 5
min. The resulting PDE activities are shown in Fig. 2 B.
Compared with the 1.9-fold activation of PDE5 in the
cGKI-containing supernatant, the cGMP-induced activa-
tion was only 1.2-fold in the cGKI-depleted sample. On re-
constitution with purified cGKI, the cGMP-induced activa-
tion was restored (2.2-fold). The respective phosphorylation
Figure 2. cGKI-mediated phosphorylation and activation of 
PDE5. (A) Platelet supernatant was incubated with 8-AET-cGMPS-
agarose to remove cGKI. Immunoblot analysis using an anti-cGKI 
antibody (top) is shown after incubation of the supernatant with 
control agarose (lane 1, cGK-containing), the cGMP-agarose (lane 2, 
cGK-depleted) and after reconstitution of the cGMP-agarose–treated 
supernatant with recombinant cGKI (lane 3, cGK-reconstituted). An 
anti-PDE5 antiserum (bottom) was used to control PDE5 content 
after incubation with cGMP-agarose (B) The obtained supernatants 
were preincubated with 100  M cGMP for 5 min, diluted, and 
PDE activity was subsequently determined. Data represent means   
SD of three independent experiments performed in duplicate. 
(C) Phosphorylation of PDE5 and VASP was detected after the 
preincubation with 100  M cGMP using the respective phospho-
specific antibodies in Western blot analysis.
Figure 3. NO-induced cGMP signaling in platelets from cGKI
 /  
mice. (A) Platelets from cGKI
 /  or WT mice were incubated with 
300  M GSNO, and the cGMP content was determined at the 
indicated time points. Shown are means of three independent 
experiments with platelets from three WT and three cGKI
 /  mice. 
(B) Western blot analysis of untreated and NO-treated platelets 
(300  M GSNO; 1 min) using phospho-PDE5 antibody (top) and 
total VASP serum (bottom) are shown. In contrast to the phospho-VASP 
antibody, the total VASP serum recognizes unphosphorylated 
and phosphorylated VASP. A shift toward higher molecular weight 
indicates phosphorylation at Ser-157.T
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of PDE5 and VASP is shown in Fig. 2 C. These data suggest
that cGKI is responsible for phosphorylation, apparently
promoting the activation of PDE5 in platelets.
 
NO-induced cGMP response in platelets 
from cGKI
 
 
 
/
 
 
 
 mice
 
To further investigate the role of the cGKI-mediated phos-
phorylation of PDE5 within the NO-induced cGMP re-
sponse, we used platelets from cGKI-deficient mice. Fig. 3 A
shows the biphasic cGMP response of intact platelets from
wild-type (WT) and cGKI
 
 
 
/
 
 
 
 mice. Stimulation with 300
 
 
 
M GSNO led to a cGMP response similar to that seen in
human platelets, although remarkably, the duration of the
cGMP transient in mice was even shorter. However, the
cGMP response in platelets from cGKI
 
 
 
/
 
 
 
 and WT mice
did not show any differences.
To find out whether the observed shaping of the cGMP
response in the cGKI-deficient platelets was due to phos-
phorylation of PDE5, we investigated the phosphorylation
state of PDE5 in cGKI-deficient platelets. As shown in Fig.
3 B, PDE5 phosphorylation still occurred in cGKI-defi-
cient platelets, but was found to be reduced by 
 
 
 
75% as
evaluated by densitometric analysis of several immuno-
blots. In cGKI-deficient mice, phosphorylation of VASP at
Ser-157 and the concomitant mobility shift from 46 to 50
kD can be considered as a marker for cAK activation (Fig.
3 B); thus, activation of cAK in response to NO clearly oc-
curred, and very likely accounted for the observed phos-
phorylation of PDE5 in platelets from cGKI-deficient
mice. However, an unaltered cGMP response associated
with a markedly reduced phosphorylation in cGKI-defi-
cient platelets questioned the requirement of PDE5 phos-
phorylation for PDE5 activation.
 
cGMP-induced activation of PDE5 occurs independent 
of phosphorylation
 
Thus, we further investigated whether phosphorylation is re-
quired for the observed activation of PDE5 using a platelet
supernatant in which phosphorylation of PDE5 did not oc-
cur (for control, see Fig. 5 A). First, cGKI was precipitated
from platelet supernatant as described above. The superna-
tant was diluted 20-fold, and subsequently was treated with
alkaline phosphatase to degrade ATP. Then, the diluted,
cGKI- and ATP-depleted supernatant was incubated with
cGMP (50 
 
 
 
M for 1 min), and diluted again before mea-
surement of PDE activity (1 
 
 
 
M substrate). Surprisingly,
PDE5 activity was enhanced 2.3-fold in the cGMP-preincu-
bated sample as shown in Fig. 4, suggesting that cGMP by
itself is able to activate PDE5.
To monitor the time course of the reversal of cGMP-
induced activation, the cGMP-preincubated supernatant was
diluted 250-fold (to 
 
 
 
0.2 
 
 
 
M cGMP) and was further in-
cubated at 37
 
 
 
C. At the indicated time points, aliquots were
withdrawn and PDE activity was measured. As shown in
Fig. 4, the decline in PDE activity was unexpectedly slow,
increased PDE activity compared with control was still ob-
served after 60 min. These data suggest that cGMP binding
to the regulatory domain has a long-term stimulatory effect
on the catalytic rate of PDE5.
 
Phosphorylation enhances cGMP-induced activation 
of PDE5
 
However, a 100-
 
 
 
M cGMP preincubation of the undiluted
supernatant only caused a significant activation of PDE5 in
the presence of cGKI (1.8-fold vs. 1.2-fold; shown in Fig. 5
A), clearly indicating a role of the phosphorylation in the
observed activation. Although in this experiment, preincu-
bation (5 min) was started with 100 
 
 
 
M cGMP, cGMP was
completely degraded within 2 min of preincubation due to
the high PDE activity in the undiluted supernatant (unpub-
lished data). So, we hypothesized that phosphorylation en-
hanced cGMP-induced PDE5 activation, permitting activa-
tion to occur at lower cGMP concentrations. In this case, a
higher cGMP concentration during preincubation should
result in PDE5 activation even in the absence of cGKI. In-
deed, preincubation of the cGKI-depleted supernatant with
500 
 
 
 
M cGMP resulted in a 2.5-fold PDE5 activation that
was almost as pronounced as that seen in the cGKI-contain-
ing supernatant (2.9-fold; Fig. 5 A). In this experiment, 150
 
 
 
M residual cGMP was measured after 5 min of preincuba-
tion (unpublished data). These results suggest that the effect
of phosphorylation can at least be partially mimicked by
high cGMP concentrations.
In these experiments, the absence of PDE5 phosphoryla-
tion was controlled in the Western blot in Fig. 5 A. Clearly,
no phosphorylation of PDE5 occurred in the cGKI- and
ATP-depleted samples; this experiment also represents the
appropriate control for the results shown in Fig. 4.
In addition to the activation, we monitored the time
course of deactivation of the phosphorylated and unphos-
phorylated PDE5. Again, activation was sustained and still
detectable after 60 min (Fig. 5 B). In this experimental set-
ting, no significant difference in the time courses of deacti-
vation between the phosphorylated and unphosphorylated
PDE5 could be observed. In sum, the data suggest that the
cGMP-induced activation of PDE5 does not require (but is
enhanced by) phosphorylation.
Figure 4. cGMP-induced activation of PDE5 is independent of 
phosphorylation and reverses slowly. A cGKI-depleted platelet 
supernatant was diluted 20-fold and preincubated without or 
with 50  M cGMP for 1 min at 37 C in the absence of ATP and 
in the presence of 100  M Rp-8-Br-cAMPS to inhibit cAK. cGMP 
preincubation was terminated by a further 250-fold dilution into 
ice-cold dilution buffer (bar graph, showing maximal cGMP-induced 
activation) or prewarmed buffer (37 C). Aliquots were withdrawn and 
assayed for PDE5 activity at the indicated time points (line graph).T
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The NO-induced PDE5 activation and phosphorylation 
persists after scavenging NO
 
The experiments in platelet supernatant showed that
PDE5 activation is very sustained and reverses only slowly
in vitro. Next, we studied the time course of the NO-stim-
ulated activity of PDE5 in intact cells. Intact platelets were
incubated with 1 
 
 
 
M DEA-NO for 5 min, which led to a
maximal activation of PDE5 (2.4-fold). Then, a 50-fold
excess of the NO scavenger carboxy-PTIO (50 
 
 
 
M) was
added to terminate NO stimulation, and the platelets were
further incubated at 37
 
 
 
C. At the indicated time points, al-
iquots were withdrawn, platelets were lysed, and cytosolic
PDE activities were measured (Fig. 6 A, primary axis).
Scavenging of NO resulted in marked reduction of PDE5
activity within 10 min (to 
 
 
 
1.8-fold over basal). However,
after 10 min, the decline in PDE activity decelerated and a
1.5-fold activation of PDE5 was still detectable 60 min af-
ter the removal of NO. The concomitant phosphorylation
of PDE5 is presented as Western blot in Fig. 6 B; the
quantitative analysis of the immunoreactive signals dis-
played in Fig. 6 A (secondary axis) shows that the apparent
kinetics of dephosphorylation are in good accordance with
PDE5 deactivation. A substantial degree of PDE5 phos-
phorylation was still detected 60 min after addition of
the NO scavenger. These data demonstrate that the NO-
induced activation and phosphorylation of PDE5 is sus-
tained in intact cells. Thus, a short NO signal is likely to
lead to a long-lasting desensitization of the NO/cGMP sig-
naling pathway.
Figure 5. Comparison of activation and its reversal of 
phosphorylated vs. nonphosphorylated PDE5. cGKI-containing 
and -depleted platelet supernatants as described for Fig. 2 were 
preincubated with 100 or 500  M cGMP for 5 min at 37 C in the 
presence or absence of ATP, respectively. 100  M Rp-8-Br-cAMPS 
was present in both samples to inhibit cAK. (A) cGMP-induced 
activation of PDE5. The Western blot shows the concomitant 
phosphorylation of PDE5. (B) After the preincubation, samples 
were diluted 1,000-fold into dilution buffer and further 
incubated at 37 C. Aliquots were withdrawn and assayed for 
PDE5 activity at the indicated time points. Data represent
means   SD of seven independent determinations using four
different cytosolic preparations.
Figure 6. Reversal of NO-induced PDE5 activation and 
phosphorylation in intact platelets. Intact human platelets were 
incubated with 1  M DEA-NO for 5 min, and then a 50-fold excess 
of the NO scavenger carboxy-PTIO (50  M) was added. Aliquots were 
withdrawn at the indicated time points and lysed. (A) PDE activity was 
determined (circles, primary axis) and PDE5 phosphorylation was 
assessed using quantitative Western blot analysis (squares, secondary 
axis). Data represent means of 10 samples assayed for PDE activity 
and quantitative analysis of six Western blots, respectively. 
(B) Representative Western blot for detection of PDE5 phosphorylation 
(top) after the addition of carboxy-PTIO; PDE5 content of the samples 
was controlled using a PDE5 antibody (bottom).T
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Long-term desensitization of the cGMP 
response in platelets
 
To verify the proposed long-term desensitization of the
cGMP response induced by NO, we looked at the cGMP re-
sponse in intact platelets. In our recent work, we have de-
scribed a reduced cGMP response after 3 min of preincuba-
tion with NO (Mullershausen et al., 2001). Here, we
monitored the desensitization of the cGMP response 1 h af-
ter a single, comparatively low, physiologically occurring
NO stimulus (100 nM DEA-NO). As can be seen in Fig. 7
A (inset), the initial NO-induced cGMP increase elicited by
100 nM DEA-NO only leads to a very minor increase in
cGMP; for comparison, a maximal response (10 
 
 
 
M DEA-
NO) is shown in the same graph. 1 h after this NO stimu-
lus, platelets were restimulated with a maximally effective
DEA-NO concentration (10 
 
 
 
M). Clearly, the cGMP re-
sponse of the NO-preincubated platelets was reduced with
peak cGMP levels, 
 
 
 
60% of those in the control. PDE ac-
tivity was still elevated significantly (1.25-fold, P 
 
 
 
 0.002;
Fig. 7 B, bar graph), and phosphorylation of PDE5 was still
detectable (Fig. 7 B, Western blot), which very likely ac-
counts for the observed desensitization of the NO-induced
cGMP response.
 
Discussion
 
In a previous report, we showed that NO elicits a fast bipha-
sic cGMP response in human platelets and rat aorta. In
platelets, cGMP reached peak levels within 5–10 s after NO
stimulation; then, cGMP levels rapidly declined to almost
basal levels after 
 
 
 
40 s. This characteristic response indi-
cated a complex interplay of cGMP formation and degrada-
tion. In fact, the transient elevation in intraplatelet cGMP
was accompanied by activation and phosphorylation of
PDE5 within a few seconds after NO stimulation. More-
over, preincubation with NO for 3 min caused desensitiza-
tion of the signaling pathway as shown by a reduced cGMP
response on NO restimulation.
In this paper, we show that the NO-induced activation and
phosphorylation of PDE5 in human platelets was abolished
in the presence of the guanylyl cyclase inhibitor ODQ, ruling
out any other NO targets involved in PDE5 activation.
To identify further components involved in the signaling
cascade, we used supernatants from lysed platelets instead of
intact platelets. In experiments with whole platelet lysates,
the possibility that PDE5 is associated with the platelet
membranes and redistributes on NO stimulation had been
ruled out (Mullershausen et al., 2001). In the supernatant,
we were able to show that cGMP is sufficient to elicit acti-
vation and phosphorylation of PDE5. Removal of cGKI
from the platelet supernatant caused a marked reduction
of cGMP-induced PDE5 activation and phosphorylation,
whereas the addition of purified cGKI restored the ability of
cGMP to exert its effects on PDE5. These data suggested
that cGKI mediates the activation of PDE5 via phosphoryla-
tion. However, the cGMP response in platelets from cGKI
 
 
 
/
 
 
 
mice did not differ from that in WT mice, and phosphor-
ylation of PDE5, although to a substantially lower extent,
was still observed. Apparently, in the cGKI
 
 
 
/
 
 
 
 platelets, an-
other kinase, most likely cAK cross-activated by cGMP, can
phosphorylate PDE5 in response to NO. Direct activation
of cAK by cGMP has been reported to occur at 
 
 
 
10 
 
 
 
M
cGMP (Ogreid et al., 1985). Assuming a murine platelet
volume of 3.3 femtoliters (Poole, 1996), intraplatelet cGMP
concentrations transiently reach 50–100 
 
 
 
M after maximal
NO stimulation. With cGMP bound to the regulatory do-
mains of PDE5, cAK appears as a plausible candidate for
PDE5 phosphorylation in cGKI-deficient platelets. How-
ever, the discrepancy of an unaltered cGMP response and
Figure 7. Long-term desensitization of the cGMP response. 
(A, inset) Platelets were incubated with 100 nM DEA-NO and the 
cGMP content was determined at the indicated time points; for 
comparison, a maximal response (10  M DEA-NO) is represented 
by the dotted line. (A) 1 h after the addition of 100 nM DEA-NO, 
platelets were restimulated with 10  M DEA-NO and cGMP 
accumulation was measured (filled circles). In the control (open 
circles), platelets were incubated for 1 h without DEA-NO. Shown 
is one representative experiment performed in duplicate out of 
three with similar results. (B) Activity of PDE5 as detected 1 h 
after addition of 100 nM DEA-NO. Data represent means   SD 
of eight independent determinations. Asterisk indicates statistically 
significant difference between the bars (*P   0.002; unpaired 
two-tailed t test). Phosphorylation of PDE5 is shown as detected 1 h 
after addition of 100 nM DEA-NO (top blot); PDE5 content of the 
samples was controlled (bottom blot).T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
Sustained activation of PDE5 by cGMP |
 
 Mullershausen et al. 725
 
the reduced phosphorylation in platelets from cGKI
 
 
 
/
 
 
 
 mice
prompted us to further study the relationship between phos-
phorylation and activation of PDE5.
For that reason, we measured the cGMP-induced in-
crease in PDE5 activity in a platelet supernatant in which
phosphorylation of PDE5 could not occur. In this platelet
supernatant, cGKI had been removed by precipitation,
ATP had been degraded, and cGMP did not induce phos-
phorylation of PDE5 as controlled with the antibody
against the phosphorylated enzyme. Moreover, before the
actual experiment (i.e., preincubation with cGMP), the
platelet supernatant was diluted 20-fold to impede phos-
phorylation by any residual cGKI being present after pre-
cipitation. Preincubation of this platelet supernatant with
cGMP resulted in an approximately twofold increase in
PDE5 activity. It is most tempting to speculate that the in-
crease in catalytic rate is caused by binding of cGMP to the
GAF domains of PDE5. Because increased PDE activity
was sustained and still detectable 1 h after dilution, cGMP
bound to the regulatory domains can be assumed to disso-
ciate very slowly. Allosteric regulation of enzymatic activity
on cyclic nucleotide binding to the evolutionarily highly
conserved GAF domains has been demonstrated for the
cGMP-stimulated cAMP-degrading PDE type 2 (Martins
et al., 1982) and for a self-activating adenylyl cyclase class
III from the cyanobacterium 
 
Anabaena
 
 (Kanacher et al.,
2002). Although cGMP binding to the noncatalytic GAF
domains of PDE5 has been extensively studied and de-
scribed in the literature, a stimulatory effect on catalysis has
so far not been demonstrated. Only recently, activation of
recombinantly expressed PDE5 by cGMP binding to the
GAF-A domain was demonstrated by Beavo’s laboratory
(Rybalkin et al., 2003). The fact that the cGMP-induced
PDE5 activation could now be detected was probably due
to the use of fresh cytosolic preparations in each experi-
ment because the ability of cGMP to activate PDE5 was
lost on storage.
However, under some experimental conditions, phos-
phorylation of PDE5 appeared to be required for cGMP-
mediated activation, as demonstrated in Figs. 2 and 5. These
data suggested that phosphorylation facilitated cGMP-
induced PDE5 activation, allowing it to occur at a cGMP
concentration not sufficient to directly induce the activation.
And indeed, a higher cGMP concentration in the same ex-
perimental setting did cause a phosphorylation-independent
PDE5 activation (see Fig. 5 A). We conclude that cGMP
alone can activate PDE5 and that this activation is facilitated
by phosphorylation; whether this is due to an increase in af-
finity of the allosteric sites for cGMP or whether the stimu-
latory effect of bound cGMP is enhanced by phosphor-
ylation cannot be decided in our experimental setting.
Nevertheless, under physiological conditions, the NO/
cGMP-induced activation and phosphorylation of PDE5
will occur in parallel.
To verify the physiological significance of the sustained
activation of PDE5 in a cellular environment, we induced
activation of PDE5 in intact platelets with NO and moni-
tored PDE activity after scavenging residual NO. Although
a significant decline in PDE5 activity was measurable after
10 min, elevated PDE5 activities were detected for up to
1 h, suggesting the increase in PDE5 activity as a mechanism
sufficient for long-term desensitization. Our results are in
good accordance with the results published by Wyatt et al.
(1998), who found that ANP-elicited activation of PDE5 in
primary vascular smooth muscle cells was still detectable af-
ter 30–60 min.
Finally, we studied whether the observed long-lasting in-
creases in PDE5 activity seen in platelet supernatant are suf-
ficient to cause reduction of the NO-induced cGMP re-
sponse in intact platelets. Indeed, even 1 h after a single
application of a physiologically occurring NO concentra-
tion, a marked reduction of the cGMP response toward a
maximally effective NO concentration was observed. There-
fore, the enhanced degradation of cGMP appears to repre-
sent the molecular basis for the prolonged desensitization of
the NO/cGMP system.
It is tempting to speculate that the mechanism of PDE5
activation in response to NO is not limited to platelets, but
also represents a general model for negative feedback regula-
tion of the cellular cGMP turnover. This idea is supported
by a report of PDE5 activation and phosphorylation in iso-
lated vascular smooth muscle cells (Rybalkin et al., 2001).
Thus, the mechanism of an enhanced cGMP breakdown by
a sustained activation of PDE5 may very well explain the
different states of NO sensitivities found in various studies,
and may well contribute to the development of tolerance to
NO-releasing compounds observed in vascular smooth
muscle, a common problem in the treatment of coronary
heart disease.
 
Materials and methods
 
Reagents
 
Recombinant cGKI and COOH-terminal anti-cGKI-
 
 
 
 and -
 
 
 
 antibody were
purchased from Calbiochem-Novabiochem. Affinity-purified antibody to
phosphorylated PDE5 was prepared as described previously (Liu et al.,
2002). Antiserum to total VASP, mAb to Ser-239-phosphorylated VASP,
DEA-NO (2,2-diethyl-1-nitroso-oxyhydrazine), GSNO (S-nitrosogluta-
thione), ODQ, and carboxy-PTIO (2-(4-carboxyphenyl)-4,4,5,5-tetra-
methylimidazoline-1-oxyl-3-oxide) were purchased from Qbiogene. pAb
to PDE5 was raised by immunizing rabbits with an NH
 
2
 
-terminal fragment
of 50 kD human PDE5A1 coupled to GST. Agarose beads coupled to Rp-8-
AET-cGMPS (8-(aminoethyl)thioguanosine-3
 
 
 
,5
 
 
 
-cyclic monophosphoate,
Rp-isomer) and AET, and Rp-8-Br-cAMPS were obtained from Biolog.
 
 
 
[
 
32
 
P]GTP was purchased from Amersham Biosciences. Soluble guanylyl
cyclase was purified from bovine lung as described previously (Humbert et
al., 1990). All other reagents were purchased from Sigma-Aldrich.
 
Isolation of human platelets
 
Collection of blood and isolation of human platelets was performed largely
as described previously (Friebe et al., 1998). In brief, 20 ml of blood was
drawn into 4 ml ACD (85 mM trisodium-citrate, 65 mM citric acid, and
100 mM glucose) and centrifuged for 10 min at 300 
 
g
 
 and 20
 
 
 
C. Platelet-
rich plasma was collected and recentrifuged for 5 min at 1,500 
 
g
 
 and
20 C. The platelet pellet was carefully resuspended in platelet buffer (150
mM NaCl, 0.55 mM NaH2PO4, 7 mM NaHCO3, 2.7 mM KCl, 0.5 mM
MgCl2, 5 mM Hepes, pH 7.4, and 5.6 mM glucose). Suspensions were al-
lowed to rest at RT for 60 min before the start of the experiments.
Measurement of PDE activity in the supernatant fraction after 
NO incubation of intact platelets
Platelet suspensions were adjusted to 3   10
8 platelets/ml. Aliquots of 450
 l were equilibrated at 37 C for 10 min, and were stimulated with DEA-
NO. Incubation time, NO donor, and other substances were applied as in-
dicated. After the incubation, platelets were lysed by the addition of 500
 l of an ice-cold protease inhibitor cocktail (2  M pepstatin A, 0.4  M
benzamidine, 0.5 mM phenylmethylsulfonyl fluoride and 2 mM sodiumT
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vanadate, 1 mg/ml BSA, and 4 mM DTT) and brief sonication (1 pulse of
5 s) on ice using a sonifier (model B-12; Branson). After centrifugation (for 15
min at 20,000 g and 4 C), PDE activity in the supernatant was measured by
the conversion of [
32P]GMP (synthesized from  [
32P]GTP using purified
guanylyl cyclase) to guanosine and [
32P]phosphate in the presence of alka-
line phosphatase at 37 C for 10 min. Reaction mixtures contained 1  l of
the supernatants,[
32P]cGMP (100,000 cpm), 1  M cGMP, 12 mM MgCl2, 3
mM DTT, 0.5 mg/ml BSA, 2 U of alkaline phosphatase, and 50 mM trieth-
anolamine/HCl, pH 7.4, in a total volume of 0.1 ml. Reactions were
stopped by the addition of 900  l ice-cold charcoal suspension (20% acti-
vated charcoal in 50 mM KH2PO4, pH 2.3). After pelleting the charcoal by
centrifugation, [
32P]phosphate was measured in the supernatant. All PDE5
assays in this report were performed using 1  M cGMP as substrate.
Western blot detection of platelet proteins
Platelet suspensions were adjusted to 4.5   10
8 platelets/ml, unless other-
wise indicated, and equilibrated for 10 min at 37 C. Incubations were per-
formed with the indicated substances for the indicated time. Reactions
were stopped by addition of Laemmli buffer and boiling for 10 min. Pro-
teins were separated by SDS-PAGE and transferred to nitrocellulose. After
blocking of the membrane, detection was performed using antibodies spe-
cific for the respective phosphorylated or nonphosphorylated proteins.
Peroxidase-labeled secondary anti–rabbit and anti–mouse antibodies and
BioWest™ extended duration bioluminescence detection kit as substrate
(Ultra-Violet Products, Ltd.) were used. Detection of the bands was per-
formed using the BioChemi™ GDS 8000 system (Ultra-Violet Products,
Ltd.), equipped with a digital 16-bit CCD camera. Quantification of the
signals was performed using the LabWorks Image Acquisition and Analysis
software (Ultra-Violet Products, Ltd.).
Isolation of platelets from conventional cGKI knockout mice
Cyclic cGKI-deficient mice were generated as described elsewhere (Wege-
ner et al., 2002). 4–8-wk-old mice of either sex were anesthetized by chlo-
roform inhalation. Blood was collected by cardiac puncture and was drawn
into 200  l citrate buffer (0.9% NaCl, 2.7 mM trisodium citrate, 2.6 mM cit-
ric acid, and 100 mM glucose). After dilution into 500  l PBS (Ca
2 - and
Mg
2 -free), blood was centrifuged for 10 min at 100 g and 20 C. Platelet-
rich plasma was carefully removed into a solution containing 1 ml PBS and
200  l citrate buffer. Thereafter, platelet-rich plasma was respun for 10 min
at 1,000 g and 20 C, and the platelet pellet was resuspended in platelet
buffer. For measurement of intraplatelet cGMP, the suspensions were ad-
justed to 4–6   10
7 platelets/ml. For Western blot analysis, a suspension of
2.5–3.5   10
8 platelets/ml was used. After the isolation procedure, platelets
were allowed to rest for 60 min at RT before any experiment. Incubation of
platelets with GSNO and RIA of intraplatelet cGMP were performed as de-
scribed previously (Friebe et al., 1998; Mullershausen et al., 2001).
Preparation of platelet supernatants
Human platelets were freshly isolated from 60 ml of blood as described
above, with the exception that the platelet pellet obtained in the second
centrifugation step ( 5   10
9 platelets) was resuspended in 650  l of cold
lysis buffer containing 50 mM NaCl, 1 mM EDTA, 2 mM DTT, 50 mM tri-
ethanolamine/HCl, pH 7.4, and a 100-fold dilution of a protease inhibitor
cocktail (Sigma-Aldrich). After brief sonication (5 s), the lysate was ad-
justed to 150 mM NaCl and centrifuged for 15 min at 20,000 g and 4 C.
Precipitation of cGKI from platelet supernatant
For precipitation of cGKI, 300  l of the supernatant were incubated for 2.5 h
at 4 C with 60  l of a suspension of Rp-8-AET-cGMPS or AET (amino-
ethylthio-spacer) coupled to agarose beads, respectively. After gentle cen-
trifugation, supernatants were removed and used in the experiments.
Activation of PDE5 in cGKI-depleted platelet supernatants
Aliquots of cGKI-cleared or cGKI-containing platelet supernatants were
preincubated with 100  M cGMP for 5 min at 37 C in the presence of 10
mM MgCl2 and 500  M ATP. To terminate the reactions, samples were di-
luted 500-fold into ice-cold dilution buffer (0.5 mg/ml BSA, 3 mM DTT, 10
mM MgCl2, and 50 mM triethanolamine/HCl, pH 7.4). 10  l of diluted
samples were subsequently assayed for PDE activity in a total volume of
0.1 ml (5,000-fold dilution in assay). PDE assays described in this paper
were performed as described above using 1  M cGMP as substrate. PDE
activities in the supernatants varied between 8–12 nmol/min/ml at 1  M
substrate in different platelet preparations. Therefore, results are expressed
as fold activation referring to the basal, nonactivated PDE activity of the re-
spective preparation. For Western blotting, the incubations were stopped
by addition of Laemmli buffer and boiling of the samples.
Activation and deactivation of PDE5 in diluted cGKI-depleted 
platelet supernatants
Platelets supernatant prepared as described above was diluted 20-fold into
buffer containing 150 mM NaCl, 1 mM EDTA, 50 mM triethanolamine/
HCl, pH 7.4, and was treated with 55 U/ml of alkaline phosphatase for 5
min at 37 C, followed by the addition of 100  M Rp-8-Br-cAMPS for an-
other minute. Subsequently, an aliquot was withdrawn into ice-cold dilu-
tion buffer for determination of basal PDE activity. cGMP preincubation
was started by the addition of cGMP and MgCl2 to the diluted supernatant
(final concentration 50  M and 10 mM, respectively). After 1 min of prein-
cubation at 37 C, an aliquot was withdrawn and diluted into ice-cold dilu-
tion buffer for determination of maximal PDE activity. Another aliquot was
diluted 250-fold into dilution buffer prewarmed to 37 C, and aliquots were
withdrawn and put on ice at the indicated times. 50  l of the samples were
assayed for PDE activity at 1  M cGMP as substrate for 5 min in a total
volume of 100  l.
Activation and deactivation of phosphorylated 
vs. nonphosphorylated PDE5
Aliquots of cGKI-cleared or cGKI-containing platelet supernatant were
treated with alkaline phosphatase and Rp-8-Br-cAMPS as described in the
previous paragraph. An aliquot was withdrawn and diluted 1,000-fold into
ice-cold dilution buffer for determination of the basal PDE activity. cGMP
preincubation was started by addition of cGMP and MgCl2 (final concen-
tration of 100  M or 500  M cGMP and 10 mM MgCl2) in the presence of
500   M ATP (cGKI-containing supernatant), or in the absence of ATP
(cGKI-cleared supernatant) for 5 min at 37 C. An aliquot was withdrawn
and diluted 1,000-fold into ice-cold dilution buffer for determination of
maximal PDE activity. Another aliquot was diluted 1,000-fold into pre-
warmed (37 C) dilution buffer and aliquots were withdrawn and put on ice
at the indicated times. 30  l of the samples were assayed for PDE activity
at 1  M cGMP as substrate for 5 min in a volume of 100  l.
Determination of cGMP degradation during preincubation 
of supernatants
Aliquots of platelet supernatants were preincubated with 100  M or 500  M
cGMP, as described in the previous paragraph, in the presence of [
32P]cGMP
and 100 U/ml of alkaline phosphatase. Degraded cGMP was detected as 
32P
in the supernatant after the addition of ice-cold charcoal suspension (20%
activated charcoal in 50 mM KH2PO4, pH 2.3) and centrifugation.
Determination of cGMP levels in human platelets
Platelets were freshly prepared as described above; the NO incubations
and the subsequent determination of cGMP using an RIA were performed
as described previously (Mullershausen et al., 2001).
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